ecancer

ecancer.org

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

 

ecancer
M

ASCO 2022: Breast Cancer Highlights

By ecancer FEATURING Matteo Lambertini
By ecancer FEATURING Matteo Lambertini
37 views
June 17, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Featured Video

18:17
Exelixis

Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and …

Feat. K. Hanna, J. Strauss
ASCO 2022
03:59

Lecture Summary - ASCO 2022 Sacituzumab Govitecan Provides Clinicall…

ecancer

H. Rugo

13 views
21:43

ASCO 2022 on the Latest Developments in mHSPC and mCRPC

ecancer

H. Payne, K. Chi, K. Miller, L. Krabbe

238 views
10:12

ASCO 2022: ASCO and WHO to Collaborate on Quality Indicators for Can…

ecancer

A. Ilbawi

10 views
05:50

ASCO 2022 on the rEECur Trial: High-Dose Ifosfamide as a SoC for Rec…

ecancer

M. Mccabe

28 views
06:54

ASCO 2022: Head & Neck Cancer Highlights

ecancer

M. Persky

77 views
07:33

ASCO 2022: Dabrafenib + Trametinib Significantly Increases Overall R…

ecancer

E. Bouffet

69 views
28:07

ASCO 2022: Latest Updates in Prostate Cancer, Including PARPi

ecancer

E. Efstathiou, C. Sternberg, N. Shore, P. Cornford

536 views
08:05

ASCO 2022 ctDNA Analyses of the Phase III VOYAGER Trial: KIT Mutatio…

ecancer

C. Serrano

41 views
05:57

ASCO 2022 on E2211 Trial for Advanced Pancreatic Neuroendocrine Tumo…

ecancer

P. Kunz

60 views
21:40

ASCO 2022 Panel Discussion on Current Strategies and Trials on Bladd…

ecancer

P. Grivas, R. Jones, P. Cornford, K. Miller

139 views
04:07

ASCO 2022: Single-Agent PD-1 Blockade as Curative-Intent Treatment i…

ecancer

A. Cercek

64 views
06:00

ASCO 2022 on a Phase II S1800A Trial: Ramucirumab + Pembrolizumab Im…

ecancer

R. Herbst

75 views
20:12

ASCO 2022 on the Latest Updates in EGFR+ NSCLC

ecancer

B. Besse, A. Minchom, A. Passaro, E. Felip

152 views
03:17

ASCO 2022: N-803 + BCG Combination Shows Promising Results in BCG-Un…

ecancer

K. Chamie

92 views
06:32

Primary Results of the Phase III SHINE Study: Ibrutinib in Combinati…

ecancer

M. Wang

525 views
05:00

ASCO 2022 on the Adjuvant Endocrine Therapy for ER+/HER2- Breast Can…

ecancer

E. Brain

120 views
07:14

ASCO 2022 Sacituzumab Govitecan Provides Clinically Meaningful PFS B…

ecancer

H. Rugo

795 views
07:25

Updated Data From the Phase 1/2 MajesTEC-1 Study: Evaluating Teclist…

ecancer

A. Nooka

1.2K views
06:05

ASCO 2022 LUMINA Study Updates: Biomarker Guidance Allows Patients 5…

ecancer

T. Whelan

829 views
06:17

ASCO 2022 Phase III EVEREST Study Updates: Everolimus After Surgery …

ecancer

C. Ryan

65 views
05:33

ASCO 2022 ctDNA Analysis Can Help Identify the Need for Adjuvant The…

ecancer

J. Tie

103 views
03:36

ASCO 2022 Panitumumab + mFOLFOX6 Improves OS for RAS Wild-Type Left-…

ecancer

T. Yoshino

74 views
12:04

ASCO 2022: Breast Cancer Highlights

ecancer

M. Lambertini

37 views
01:57

Lecture Summary - ASCO 2022 CheckMate 9ER: aRCC pts on Nivolumab + C…

ecancer

C. Suárez

14 views
04:05

ASCO 2022 Momelotinib Superior to Danazol in Symptomatic and Anaemic…

ecancer

R. Mesa

139 views
03:54

ASCO 2022 Biomarker Analysis of the NeoALTTO Trial Provides Oncofert…

ecancer

M. Lambertini

10 views
09:52

ASCO 2022 ATHENA–MONO Phase III Trial to Evaluate Rucaparib Monother…

ecancer

B. Monk

126 views
05:57

ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan vs. Treatment of …

ecancer

S. Modi

218 views
05:41

ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan Doubles PFS in MB…

ecancer

S. Modi

37 views